Roche raises Genentech bid to $45.7 billion
This article was originally published in Scrip
Executive Summary
Roche has raised its hostile offer to buy out Genentech's minority shareholders to $93 per share from $86.50. The $45.7 billion bid for the 44% of the US biotech that it does not already own is Roche's largest offer to date.